Previous studies show that expression of FANCF is reduced in various human tumors, our results imply the patient with low expression of FANCF might have higher sensitivity to chemotherapy drugs in breast cancers, FANCF may therefore prove to be a novel biomarker for sensitivity to MX-based chemotherapy in breast cancers. This evidence concerns the gene FANCF and breast cancer.